BioHarvest Sciences Inc., today unveiled the composition profile of its full-spectrum Cannabis produced in large-scale industrial bioreactors.
It is claimed that the composition profile includes the Cannabinoids THC, CBD, CBG, THCV, CBDV and CBC, as well as the Terpenes Beta-caryophyllene, Beta-panasinsene and Selina.
While other minor Cannabinoids are present, their identity determination requires further work on the measurement techniques as the current conventional ones are not advanced enough to deal with such a distinctive Cannabinoids profile. The profile and ratio between the various Cannabinoids found in BioHarvest’s product is unique and sets a path for both potential patentability and applicability to address medical indications such as ADHD, pain management and anxiety.
More quantitative information about the profile will be revealed by the company by September 15th, 2022.
In the interim though, the company confirms with certainty the significance of THC, CBD and CBG quantities inside the unique Cannabis composition.
“These achievements are remarkable and demonstrate the ability to produce unique and consistent Cannabis compositions that would have been impossible using conventional agriculture,”
Prof. Zohar Kerem, Head of the Food Chemistry Labs of the Robert H. Smith Faculty of Agriculture, Food and Environment of the Hebrew University of Jerusalem.
“I have been closely watching the application of BioHarvest’s Bio-Plant CELLicitation™ technology to Cannabis, and I am confident that advanced analysis techniques will become available soon to further unveil the Cannabinoids richness of the unique BioHarvest’s compositions.”
One of the special characteristics claimed of this Cannabis product is that it is made of trichomes representing 93% of the biomass.
Trichomes are the plant’s natural “mini-factories” that produce the active Cannabis ingredients (Cannabinoids, terpenes and other phytochemicals). Unlike conventional Cannabis products where a significant part of the biomass includes other parts of the flower which have a bitter taste, BioHarvest’s product is primarily composed of trichomes. This significant reduction of bitterness renders the product easier to integrate in food and beverage applications.
Moreover, the unique conformation of our trichomes (amalgamated in a coral shape structure) may provide for enhanced solubility and bio-availability of the product. This would allow administration of lower doses to achieve the same desired effects, which would otherwise require a higher quantity in the case of conventionally cultivated Cannabis products.
“Our consistent, clean and efficacious Cannabis, produced with the highest ESG credentials and capital efficiency, has received a significant boost with the latest conclusive composition profile information,”
said CEO Ilan Sobel.
“This rich full-spectrum combination of Cannabinoids and Terpenes with unique ratios is very promising for addressing medical conditions otherwise treated by synthetic drugs with significant negative side effects. The reduced bitterness taste and the potential improved solubility of our products amount to a game-changer for integration of full-spectrum Cannabis into the food & beverage industry.”
BioHarvest plans to bring its first Cannabis products to market in 2022.